ReViral Competitors and Similar CompaniesClear all
ReViral's competitors and similar companies include Lung Therapeutics, Vast Therapeutics and Temisis Therapeutics.
 Lung Therapeutics Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease. |  Vast Therapeutics Vast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases. |  Temisis Therapeutics Temisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component. | ||
Founding Date | Founding Date 2011 | Founding Date 2013 | Founding Date 2017 | Founding Date N/A |
Type | Type Private | Type Private | Type Subsidiary | Type Private |
Tags | ||||
Locations | Locations Stevenage, GB HQ Durham, US | Locations Austin, US HQ | Locations Durham, US HQ | Locations Vandœuvre-lès-Nancy, FR HQ |
Employees | Employees 5 | Employees 10 | Employees 12 | Employees 2 |
Funding | ||||
Latest funding round | Latest funding round $ 44m (almost 6 years ago) | Latest funding round $ 36m (about 7 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 121m | Total funding raised $ 53.9m | Total funding raised $ 15m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Lung Therapeutics
HQ
Austin, US
Employees
10
Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease.
View companyVast Therapeutics
HQ
Durham, US
Vast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases.
View companyTemisis Therapeutics
HQ
Vandœuvre-lès-Nancy, FR
Employees
2
Temisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component.
View company